非瑟酮用于养老院COVID-19:新冠时代衰老细胞清除试验
本文阐述在养老院老年居民中开展非瑟酮(一种衰老细胞清除剂)治疗SARS-CoV-2感染的随机对照试验的原理与设计。衰老细胞通过SASP加剧炎症和组织损伤,与COVID-19重症风险相关;非瑟酮可选择性清除衰老细胞。文章还讨论了在长期护理机构开展试验的后勤挑战与解决方案。
要点
- 衰老细胞负担随年龄和慢性病增加,与SARS-CoV-2感染不良结局风险相关。
- 非瑟酮等衰老细胞清除剂在动物模型中可延缓或减轻多种年龄相关疾病。
- 正在开展针对养老院SARS-CoV-2阳性老年人的多中心安慰剂对照非瑟酮试验。
核心结论
- 靶向衰老细胞可能是减轻养老院老年人SARS-CoV-2感染进展和不良结局的潜在策略。
研究设计与样本
- 美国国立卫生研究院资助的多中心、安慰剂对照临床试验,对象为SARS-CoV-2 rtPCR阳性的养老院老年居民。
主要发现
- 衰老细胞通过衰老相关分泌表型(SASP)产生与COVID-19细胞因子风暴和多器官衰竭相关的因子。
- 非瑟酮在老年实验动物和人类慢性病动物模型中可选择性清除衰老细胞并延缓或减轻多种疾病。
- 衰老细胞清除剂正在针对衰弱、肥胖/糖尿病、骨质疏松、心血管、肾脏和肺部疾病等进行临床试验。
临床怎么用
- 在养老院环境中开展干预性临床试验需考虑访问限制、知情同意、生物样本采集、人员配置和研究产品给药等后勤挑战。
- 文章提出建立参与干预性临床试验的全国养老院网络。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The burden of senescent cells (SnCs), which do not divide but are metabolically active and resistant to death by apoptosis, is increased in older adults and those with chronic diseases. These individuals are also at the greatest risk for morbidity and mortality from SARS-CoV-2 infection. SARS-CoV-2 complications include cytokine storm and multiorgan failure mediated by the same factors as often produced by SnCs through their senescence-associated secretory phenotype (SASP). The SASP can be amplified by infection-related pathogen-associated molecular profile factors. Senolytic agents, such as Fisetin, selectively eliminate SnCs and delay, prevent, or alleviate multiple disorders in aged experimental animals and animal models of human chronic diseases, including obesity, diabetes, and respiratory diseases. Senolytics are now in clinical trials for multiple conditions linked to SnCs, including frailty; obesity/diabetes; osteoporosis; and cardiovascular, kidney, and lung diseases, which are also risk factors for SARS-CoV-2 morbidity and mortality. A clinical trial is underway to test if senolytics decrease SARS-CoV-2 progression and morbidity in hospitalized older adults. We describe here a National Institutes of Health-funded, multicenter, placebo-controlled clinical trial of Fisetin for older adult skilled nursing facility (SNF) residents who have been, or become, SARS-CoV-2 rtPCR-positive, including the rationale for targeting fundamental aging mechanisms in such patients. We consider logistic challenges of conducting trials in long-term care settings in the SARS-CoV-2 era, including restricted access, consent procedures, methods for obtaining biospecimens and clinical data, staffing, investigational product administration issues, and potential solutions for these challenges. We propose developing a national network of SNFs engaged in interventional clinical trials.
引用
- Verdoorn BP, Evans TK, Hanson GJ, et al. Fisetin for COVID-19 in skilled nursing facilities: Senolytic trials in the COVID era. J Am Geriatr Soc. 2021. PMID: 34375437. doi:10.1111/jgs.17416
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。